Dr Lindsay E Clegg (Postdoctoral Fellow at AstraZeneca) discusses EXSCEL - Cardiovascular and renal outcomes with combination exenartide and open-label SGLT2 inhibitor treatment in EXSCEL.
1. What was the rationale behind the EXSCEL trial?
2. What was the study design and inclusion criteria?
3. Could you summarise the CV and renal outcomes of the study?
4. How does it compare to data seen in other SGLT2 outcome studies?
5. What impact this could have on clinical practice?
6. How will this data influence further research in the field?
Filmed on site at EASD 2019 by Radcliffe Cardiology.
Interviewer: Mirjam Boros
Videographer: Dave Good